Literature DB >> 16277979

Extra domain A and type III connecting segment of fibronectin in assembly and cleavage.

Yasunori Abe1, Ngoc-Anh Bui-Thanh, Christie M Ballantyne, Alan R Burns.   

Abstract

To determine the role of the extra domain A (EDA) and type III connecting segment (IIICS) of fibronectin in fiber assembly, topographical distribution and proteolytic cleavage, eight full-length human fibronectin cDNA variants (aa0, aa64, aa89, and aa120 variations in the IIICS with or without the EDA) tagged with the V5 epitope were cloned from human endothelial cells and were expressed in CHO-K1 cells. All eight variants were assembled on cell surfaces. However, only the EDA(+) variants, regardless of the type of the IIICS domain, formed extensive fibrous networks. In contrast, the EDA(-)/aa64 and EDA(-)/aa89 variants were present predominantly as a soluble form. Western analysis of both soluble and cell-associated fibronectin/V5 variants showed that aa64, aa89, and aa120 variants with or without the EDA domain produced the major 50- to 62-kDa C-terminal fragments, whereas the aa0 variants did not, suggesting that the IIICS domain provides proteolytic cleavage sites.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16277979     DOI: 10.1016/j.bbrc.2005.10.134

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Ligation of the fibrin-binding domain by β-strand addition is sufficient for expansion of soluble fibronectin.

Authors:  Lisa M Maurer; Wenjiang Ma; Nathan L Eickstaedt; Ian A Johnson; Bianca R Tomasini-Johansson; Douglas S Annis; Deane F Mosher
Journal:  J Biol Chem       Date:  2012-02-20       Impact factor: 5.157

2.  Engineered Fibrillar Fibronectin Networks as Three-Dimensional Tissue Scaffolds.

Authors:  Stacy Jordahl; Luis Solorio; Dylan B Neale; Sean McDermott; Jacob H Jordahl; Alexandra Fox; Christopher Dunlay; Annie Xiao; Martha Brown; Max Wicha; Gary D Luker; Joerg Lahann
Journal:  Adv Mater       Date:  2019-09-30       Impact factor: 30.849

3.  Fibronectin extra domain-A promotes hepatic stellate cell motility but not differentiation into myofibroblasts.

Authors:  Abby L Olsen; Bridget K Sackey; Cezary Marcinkiewicz; David Boettiger; Rebecca G Wells
Journal:  Gastroenterology       Date:  2011-12-24       Impact factor: 22.682

4.  Substance P is responsible for physiological alterations such as increased chloride ion secretion and glucose malabsorption in cryptosporidiosis.

Authors:  Julio Hernandez; Andrew Lackner; Pyone Aye; Kakali Mukherjee; David J Tweardy; Mary-Ann Mastrangelo; Joel Weinstock; Jeffrey Griffiths; Melinda D'Souza; Shantu Dixit; Prema Robinson
Journal:  Infect Immun       Date:  2006-12-11       Impact factor: 3.441

5.  Plasma and cellular fibronectin: distinct and independent functions during tissue repair.

Authors:  Wing S To; Kim S Midwood
Journal:  Fibrogenesis Tissue Repair       Date:  2011-09-16

6.  IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC).

Authors:  Petra Richter; Kerstin Junker; Marcus Franz; Angela Berndt; Christiane Geyer; Mieczyslaw Gajda; Hartwig Kosmehl; Alexander Berndt; Heiko Wunderlich
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-03       Impact factor: 4.553

7.  Quantification of fibronectin 1 (FN1) splice variants, including two novel ones, and analysis of integrins as candidate FN1 receptors in bovine preimplantation embryos.

Authors:  Karen Goossens; Ann Van Soom; Alex Van Zeveren; Herman Favoreel; Luc J Peelman
Journal:  BMC Dev Biol       Date:  2009-01-06       Impact factor: 1.978

8.  Tissue-specific and SRSF1-dependent splicing of fibronectin, a matrix protein that controls host cell invasion.

Authors:  Isabel Cristina Lopez-Mejia; Marion De Toledo; Flavio Della Seta; Patrick Fafet; Cosette Rebouissou; Virginie Deleuze; Jean Marie Blanchard; Christian Jorgensen; Jamal Tazi; Marie-Luce Vignais
Journal:  Mol Biol Cell       Date:  2013-08-21       Impact factor: 4.138

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.